OncoHost to Showcase Innovative Research on Aging Biomarkers at AACR 2026
OncoHost to Present New Research on Proteomic Aging Biomarkers Outcomes at AACR 2026
OncoHost, an innovative technology firm specializing in precision oncology, has gained acceptance to showcase its latest findings at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026, scheduled from April 17 to 22 in San Diego, California. OncoHost's research underscores the role of proteomic aging biomarkers in predicting treatment outcomes for patients undergoing immunotherapy.
The study, titled "Proteomic Aging Biomarkers Predict Survival in Immunotherapy-Treated Tumors," examines how biological aging correlates with different tumor types and patient responses. By utilizing advanced proteomic analytics, the research aims to quantify biological aging and its relationship with immunity and cancer prognosis.
Dr. Michal Harel, the Vice President of Translational Medicine at OncoHost and lead author of the study, remarked, "This research broadens our comprehension of how both systemic and organ-specific aging processes affect cancer biology and responses to treatments like immunotherapy. By assessing biological aging across various tissues, we aim to discover clinically significant signals that improve patient stratification beyond conventional biomarkers."
The findings highlight a concerning trend: cancer patients show marked biological aging compared to healthy individuals. Variations were especially pronounced with certain cancers, such as non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), indicating the lung's biological age diverges significantly from that of healthy subjects. The study also connects organ-specific aging trends to common comorbidities, suggesting a complex interrelationship between aging and cancer development.
One crucial aspect of the research delves into the prognostic value of immune-specific aging. Among patients treated with immune checkpoint inhibitors, those with a higher immune age showed notably shorter overall survival rates than those with lower immune age. For instance, the median overall survival for patients with a high immune age gap was just 16.4 months, compared to 31.8 months for those with a lower immune age. This effect varied based on the type of cancer, with melanoma exhibiting a particularly significant finding, thus highlighting differences in tumor immunogenicity.
Ofer Sharon, CEO of OncoHost, expressed pride in being selected for this presentation at AACR. "Highlighting the importance of moving beyond the tumor-centric approach, we’re quantifying biological aging across the body and its impact on cancer progression and treatment efficacy. This could revolutionize how we guide immunotherapy, leading to smarter treatment decisions and better patient outcomes."
Poster Presentation Details
- - Title: Proteomic Aging Biomarkers Predict Survival in Immunotherapy-Treated Tumors
- - Session Title: Biomarkers Predictive of Therapeutic Benefit 3
- - Poster Board: 22
- - Presenters: Michal Harel, PhD, VP Translational Medicine, OncoHost and Adam Dicker, MD, PhD, Chief Medical Officer, OncoHost
- - Date and Time: Monday, April 20, 2026, from 9:00 AM to 12:00 PM PDT
In conclusion, OncoHost continues to push the boundaries of precision medicine through a deep understanding of the biological processes underpinning cancer treatment. By connecting aging biomarkers to clinical outcomes, the firm is at the forefront of potentially transformative approaches in oncology's future. For more information on OncoHost's innovative research and technologies, visit www.oncohost.com and follow them on LinkedIn, X (Twitter), Facebook, and YouTube.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.